Therefore, the aim of this study was to establish whether IL-17A gene promoter methylation is associated with the incidence of different stages of CAD, i.e., subclinical atherosclerosis and CAD with clinical manifestations. This evidence concerns the gene IL17A and coronary artery disorder.